Xultophy® Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi
Copenhagen, Denmark (ots/PRNewswire) - New findings from an indirect comparison between Xultophy® and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy® (insulin degludec/liraglutide) provides statistically significant greater reductions in blood sugar levels and body weight ...